NTD targeting NAbs show high potency but the exact mechanism is still unclear
- NAb 4A8
- NAb 7D10

NAbs targeting NTD of spike protein

have rarely been reported, but since S2 subunit is more sequentially conserved, it might be helpful to screen for broad S2 specific NAbs
- mAb 1A9

NAbs targeting S2 subunit of spike protein

- NAbs targeting NTD of spike protein
- NAbs targeting S2 subunit of spike protein

State University of New York at Stony Brook

Infection by SARS-CoV-2 triggers the creation of antibodies in a two-part response: 
- early antibodies (IgM)
- late antibodies (IgG)

With assistance from helper T cells, B cells differentiate into plasma B cells to produce these antibodies against the SARS-CoV-2 antigens.

Antibodies and COVID-19 

Huang, Y., Sun, H., Yu, H., Li, S., Zheng, Q., & Xia, N. (2020). Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective. Antibody Therapeutics, 3(4), 285-299.
https://doi.org/10.1093/abt/tbaa028

Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective 

- Antibody Therapeutics
-  MedRxiv Preprint Papers
- Preprints
- Science

References for Antibodies and COVID-19 by journal

A study showed that SARS neutralizing antibodies can successfully block SARS-CoV-2 entry into target cells in vitro, suggesting that the two viruses possess a cross-protective epitope and have similar immune protection against reinfection

SARS neutralizing antibodies and SARS-CoV-2


-  Support for the use of SARS-CoV-2 Ab for therapies
-  Evidence suggesting SARS-CoV-2 Ab may not be the most viable solution

SARS-CoV-2 Antibodies and their uses in future SARS-CoV-2 Therapies

- Type I: only binds to 'up' RBD
- Type II: only binds when at least 2 RBD are 'up'
- Type III: only binds to 'down' RBD
- Type IV: recognizes both 'up' and 'down' RBD
- the image below shows the antibody interactions with RBD to the left and antibodies to the right

Learn Before

Related

Learn After